Ipca Labs subsidiary acquires 80% stake in Bayshore Pharmaceuticals for USD 10.28 mn
NEW DELHI: Pharmaceutical firm Ipca Laboratories has recently announced the acquisition of 80 per cent stake in US' Bayshore Pharmaceuticals LLC by its subsidiary for USD 10.286 million (approx Rs 75.40 crore).
The acquisition of the majority stake in Bayshore by Ipca Labs' wholly-owned subsidiary will enable the company to commercialise its registered generics drug products in the US market through this entity, Ipca Laboratories said in a regulatory filing.
"The company's wholly-owned subsidiary, Ipca Pharmaceuticals Inc., USA, has acquired, on October 2, 2018, 80 per cent share capital of Bayshore Pharmaceuticals LLC, a New Jersey limited liability company ...for cash USD 10.286 million," it added.
For its financial year ended December 31, 2017, Bayshore had a total income of USD 7.05 million.
Read Also: Over 75 percent of Indian drug import comes from China says pharma body IPCA
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd